SPOTLIGHT -
EP. 1: Managing Adjuvant Treatment in Colorectal Cancer, Part I
EP. 2: Managing Adjuvant Treatment in Colorectal Cancer, Part II
EP. 3: Understanding the Role of Aspirin in Colorectal Cancer
EP. 4: Exploring the Neoadjuvant Treatment of Rectal Cancer
EP. 5: Treating Resectable Metastatic Colorectal Cancer
EP. 6: Treating Unresectable Metastatic Colorectal Cancer
EP. 7: Treatment Sequencing in Metastatic Colorectal Cancer
EP. 8: Determining Optimal Treatments in mCRC
EP. 9: Second-Line Therapies for Patients With mCRC
EP. 10: Case Study: Treating Metastatic Colorectal Cancer
EP. 11: Conclusion: Optimal Side Effect Management in CRC
Tusamitamab Ravtansine Plus Pembrolizumab With or Without Chemo Elicits Responses in CEACAM5+ NSCLC
Cemiplimab Monotherapy Induces Durable OS, PFS Benefits in PD-L1+ NSCLC With Brain Metastases
Four Cycles of Chemotherapy Plus Tremelimumab and Durvalumab Demonstrate Optimized Outcomes in Metastatic NSCLC
Taletrectinib Elicits Durable Responses in TKI-Naïve and Crizotinib-Pretreated ROS1+ NSCLC
